COMPANY PROFILE
| Price and Volume | |
|---|---|
| Recent Price | 6.27 |
| 52 Week High | 9.13 |
| 52 Week Low | 4.61 |
| Avg. Daily Vol. (Mil) | 4.53 |
| Beta (3 year) | 0.84 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,955.76 |
| Shares Out (Mil) | 471.41 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.80 |
| Current Ratio | 2.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | N.A. |
| Valuation Ratios | |
| Price Earnings | 57.00 |
| Price/Sales | 2.73 |
| Price/Book | 0.00 |
| Price/Cash Flow | -65.10 |
| Per Share Data | |
| Earnings | 0.11 |
| Sales | 2.30 |
| Book Value | 0.00 |
| Cash Flow | -0.10 |
| Business Summary | |
|---|---|
| A neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. | |
| General Information | |
| Treasury Building
Lower Grand Canal Street Dublin 2, |
|
| 0.99999998017957 | |
| www.elan.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1687 | |
| CEO: G. Kelly Martin | |
| Short Interest | |
| Current Month (Mil) | 12.84 |
| Previous Month (Mil) | 10.51 |
| Short Interest Ratio (Days) | 1.70 |
| Management Effectiveness | |
| Return on Equity | N.A. |
| Return on Assets | -5.00 |
| Return on Investments | -6.10 |
| Profitability | |
| Gross Margin | 54.90 |
| EBIT Margin | -13.20 |
| Profit Margin | 4.70 |